Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2020; 10(11): 40-49


In silico studies on pyrazine derivatives for identifying potential inhibitors of PIM-1 kinase

Amena Ali, Abuzer Ali, Mohd. Washid Khan, Abutahir, Ibraheem Husain, Kuldeep Patel, Vivek Asati.




Abstract
Cited by 0 Articles

PIM-1 kinase (PIM-1K) modulates multiple cellular functions and is evolving as a drug target for cancer. In search of potential PIM-1 inhibitors, we report herein the 3D-QSAR as well as docking studies on 3-(pyrazin-2-yl)-1H-indazole derivatives. Based on the 3D-QSAR study, the generated pharmacophore was utilized for the virtual screening of thousands of compounds (compds) from ZINC database against PIM-1K. Four top-ranked compds, ZINC05885218, ZINC05888770, ZINC08652441, and ZINC73096248, were selected by virtual screening study. The study results of molecular docking suggested that certain key residues were significant for interactions of ligand–receptor due to the formation of hydrogen bonds with Glu171, Glu121, Lys67, Asp128, Asp131 and Asp186 of PIM-1K. Virtually screened compds displayed resemblance in binding interactions within the PIM-1Ks catalytic pocket in comparison with their corresponding crystal structures. The ADRRR.2 emerged as the potential pharmacophore hypothesis and was employed for the generation of model of 3D-QSAR which gave good statistical values of q2 and r2 using partial least square analyses (r2 = 0.922, q2 = 0.8629) for the best model. The study results revealed that ZINC73096248 could serve as a prototype compd for developing novel PIM-1K inhibitors.

Key words: Anticancer, PIM-1 kinase, Docking, 3D-QSAR, ZINC database






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.